Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis
ACR Open Rheumatol. 2023;5(2):63–70 doi: 10.1002/acr2.11517
Data show that the first-in-class MK2 pathway inhibitor ATI-450 was well tolerated and induced sustained anti-inflammatory efficacy over 12 weeks in patients with moderate-to-severe RA.
Inflammation driven by p38 mitogen-activated protein kinase (p38 MAPK) signalling pathway is specifically mediated by the downstream serine and threonine kinase, MAPK-activated protein kinase 2 (MK2). ATI-450 is a selective, orally available MK2 pathway inhibitor with a novel mode of inhibition.
In this phase IIa study, Gordon, et al. evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of ATI-450 with methotrexate in patients with RA.
